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The conjugation of arginine, by arginyl-transferase, to N-terminal
aspartate, glutamate or oxidized cysteine is a part of the N-end rule
pathway of protein degradation. We report that arginyl-trans-
ferase of either the mouse or the yeast Saccharomyces cerevisiae
is inhibited by hemin (Fe3-heme). Furthermore, we show that
hemin inhibits arginyl-transferase through a redox mechanism that
involves the formation of disulfide between the enzyme’s Cys-71
and Cys-72 residues. Remarkably, hemin also induces the protea-
some-dependent degradation of arginyl-transferase in vivo, thus
acting as both a ‘‘stoichiometric’’ and ‘‘catalytic’’ down-regulator
of the N-end rule pathway. In addition, hemin was found to
interact with the yeast and mouse E3 ubiquitin ligases of the N-end
rule pathway. One of substrate-binding sites of the yeast N-end
rule’s ubiquitin ligase UBR1 targets CUP9, a transcriptional repres-
sor. This site of UBR1 is autoinhibited but can be allosterically
activated by peptides that bear destabilizing N-terminal residues
and interact with two other substrate-binding sites of UBR1. We
show that hemin does not directly occlude the substrate-binding
sites of UBR1 but blocks the activation of its CUP9-binding site by
dipeptides. The N-end rule pathway, a known sensor of short
peptides, nitric oxide, and oxygen, is now a sensor of heme as well.
One function of the N-end rule pathway may be to coordinate the
activities of small effectors, both reacting to and controlling the
redox dynamics of heme, oxygen, nitric oxide, thiols, and other
compounds, in part through conditional degradation of specific
transcription factors and G protein regulators.
arginylation  ATE1  ubiquitin  UBR1
The N-end rule relates the in vivo half-life of a protein to theidentity of its N-terminal residue. The ubiquitin (Ub)-
dependent N-end rule pathway recognizes several kinds of degra-
dation signals (degrons), including a set called N-degrons (Fig. 1A)
(1–6). One essential determinant of N-degron is a protein’s desta-
bilizing N-terminal residue. The N-end rule has a hierarchic struc-
ture (Fig. 1A). In eukaryotes, N-terminal Asn and Gln are tertiary
destabilizing residues in that they function through their enzymatic
deamidation, to yield the secondary destabilizing residues Asp and
Glu (1, 6). The activity of N-terminal Asp and Glu requires their
conjugation to Arg, by ATE1-encoded isoforms of Arg-tRNA-
protein transferase (arginyl-transferase or R-transferase) (2–4, 7).
Arg is one of the primary destabilizing N-terminal residues, which
are recognized by E3 Ub ligases of the N-end rule pathway, called
N-recognins (Fig. 1A) (6, 8, 9). In eukaryotes that produce nitric
oxide (NO), the set of destabilizing residues contains Cys as well
(Fig. 1A) (3). The arginylation of N-terminal Cys must be preceded
by its oxidation to Cys-sulfinate or Cys-sulfonate, a process that
requires NO in vivo (3). The N-end rule pathway is thus a sensor of
NO, through the ability of this pathway to destroy a subset of
proteins with N-terminal Cys, at rates controlled by NO, and by
oxygen as well (Fig. 1A) (3, 4).
The functions of the N-end rule pathway include regulation of
signaling by transmembrane receptors, through the NO/O2-
dependent degradation of G protein regulators RGS4, RGS5 and
RGS16; regulation of import of short peptides, through degrada-
tion of the import’s repressor CUP9; fidelity of chromosome
segregation, through degradation of a separase-produced cohesin
fragment; regulation of apoptosis, through degradation of a
caspase-processed inhibitor of apoptosis; regulation of the HIV
replication cycle, through degradation of HIV integrase; a multi-
tude of processes mediated by the transcription factor c-FOS, a
conditional substrate of the N-end rule pathway; as well as regu-
lation ofmeiosis, neurogenesis, pancreatic functions, cardiovascular
development, and leaf senescence in plants (refs. 3–8 and 10–12,
and references therein).
Heme is an iron-containing protoporphyrin IX. Two major
species of heme are ferrous (Fe2) heme and its ferric (Fe3)
counterpart, called hemin. Intracellular proteins whose functions
depend on their binding to heme include hemoglobins, cytochrome
oxidases, NO synthases, catalases, and cGMP cyclases, as well as
specific kinases, transcription factors, ion channels, and regulators
of iron metabolism (refs. 13–23 and references therein). A major
aspect of heme is its ability to interact with physiologically relevant
gases such as O2, NO and carbon monoxide (CO). Several hemo-
proteins, including cytochrome oxidase and NO synthases, contain
hemin (Fe3-heme) rather than Fe2-heme as an essential pros-
thetic group (15). Although the bulk of intracellular heme is
sequestered in major hemoproteins such as hemoglobin and cyto-
chrome oxidase, there is also a pool of ‘‘exchangeable’’ heme. In
vivo regulation of this pool, including redox-mediated transitions
between Fe2-heme and hemin, is not well understood, and is likely
to involve heme chaperones.
Wenow show thatmammalian and yeastR-transferases (ATE1s)
(Fig. 1A) are heme-binding enzymes whose arginylation activity is
inhibited by hemin, through the redox-based formation of disulfide
between vicinal Cys-71 andCys-72 ofmouseATE1.Heminwas also
found to interact with yeast andmouseUb ligases of the N-end rule
pathway (Fig. 1A). The binding of hemin to S. cerevisiae UBR1 is
shown to block the activation of one of its substrate-binding sites.
Remarkably, hemin was also discovered to induce the proteasome-
dependent degradation of R-transferase in vivo, thus acting as both
a ‘‘stoichiometric’’ and ‘‘catalytic’’ down-regulator of theN-end rule
pathway.
Results and Discussion
Heme Binds to R-Transferase. ATE1/ mice, which lack arginyla-
tion, died as embryos with cardiovascular defects (7). The levels of
both heme and embryonic -globin chain were reduced inATE1/
embryos [supporting information (SI) Fig. 6 A and C]. Conversely,
the activity of heme oxygenase, which catabolizes heme (23), was
higher in ATE1/ embryos (SI Fig. 6B). Both metazoan and yeast
R-transferases contain Heme Regulatory Motifs (HRMs), which
occur in a subset of heme-binding proteins and contain the char-
acteristic sequence Cys-Pro (13, 17, 23). C71C72P and HSC411P, two
of the four HRM-like motifs in mouse ATE1, are conserved in
ATE1s of distant species (Fig. 1 B–D). Gel filtration of hemin
(Fe3-heme) and purified ATE1, as well as hemin–agarose affinity
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chromatography with mouse cell extracts indicated the binding of
hemin to mouse ATE11B7A and ATE11A7A, two isoforms of mouse
R-transferase (Fig. 2C and SI Fig. 6 E and G). [‘‘ATE1’’ is used
interchangeably with ‘‘R-transferase’’ (2).] Gel filtration-based
spectroscopic assays (16–18) revealed the characteristic Soret band
at 372 nm, with a shoulder at 423 nm, indicating a complex of hemin
and R-transferase, as distinguished from free hemin (Fig. 2C).
Negative controls included proteins such as lysozyme, which does
not bind to hemin (Fig. 2C). The results of tryptophan fluorescence
quenching assay suggested that ATE11B7A contains a hemin-
binding site with the apparent Kd of 0.15 M, and possibly a
second hemin-binding site as well, with the apparentKd of3.2M
(Fig. 2D and SI Fig. 7 A–C). The corresponding Kd values for
ATE1C411A, the C4113A411 mutant in the C-terminal HRMmotif
(Fig. 1C), were 1.2 M and 13 M, respectively (Fig. 2D),
suggesting the relevance of this HRM, as well as the presence of
more than one hemin-binding site in ATE1, in agreement with
analyses of several other ATE11B7A mutants (SI Figs. 6E and 8).
Hemin Inhibits Arginylation by R-Transferase.Hemin at 5 and 10M
inhibited either the mouse or yeast R-transferases by more than
90% and 95%, respectively, as measured by the 14C-Arg-based in
vitro arginylation assay (2, 3) (Fig. 2). Neither FeCl3, nor proto-
porphyrin IX (heme without iron), nor Zn2-protoporphyrin had
this effect (SI Fig. 9A). Another control showed that Arg-tRNA
synthetase was not significantly inhibited by hemin (SI Fig. 9B).
Arginylation assay was also carried out under argon, with the
reduction of hemin to Fe2-heme by dithionite (17). At 5 M,
Fe2-heme inhibited mouse ATE1 by5%, whereas the inhibition
by hemin (at the same concentration) exceeded 90% (Fig. 2B).
Thus, in contrast to hemin, Fe2-hememay not inhibit ATE1 at all,
a finding whose significance becomes clear below. The inhibition of
ATE1 by hemin did not involve a trans-acting oxidizing compound
such as H2O2, because the inhibition was unaltered by catalase (SI
Fig. 7 A and B). A thiol-reducing compound such as 2-mercapto-
ethanol could rescue60% of the activity of hemin-treated ATE1
(Fig. 2B). Together, these results suggested that the binding of
hemin to ATE1 may lead to a redox-mediated modification of its
critical Cys residue(s).
Hemin-Induced Disulfide in R-Transferase.Hemin-ATE1 interactions
did not result in formation of a dimer or oligomer of ATE1 (data
not shown). We are not aware of precedents for a hemin-induced
intramolecular disulfide that alters activity of an enzyme. However,
in non-heme contexts the activity-altering intramolecular SOS
bonds were demonstrated with several cytosolic and nuclear pro-
teins (ref. 24 and references therein). To determine whether
hemin-ATE1 interactions result in an intramolecular disulfide, we
used selective labeling of thiols with fluorescein-5-maleimide (FM)
(Fig. 3C and SI Fig. 10 C–F). At most, trace amounts of FM-
conjugated ATE1 were present in the sample that had not been
treated with hemin (SI Fig. 10 C–F, lane 2). In contrast, hemin-
treated ATE1 contained significant levels of FM (SI Fig. 10 C and
D, lane 1, and E, lanes 3 and 4). To identify specific disulfide-
Fig. 1. Heme-mediated regulation of the N-end rule pathway. (A) The
mammalian N-end rule pathway. N-terminal residues are indicated by single-
letter abbreviations for amino acids. Yellow ovals denote the rest of a protein
substrate. A notation, upward of ‘‘hemin’’ in the middle of diagram, is a
‘‘down-regulation’’ sign that denotes, specifically, a down-regulation of a
target macromolecule that is mediated, at least in part, by target’s degrada-
tion. MetAPs, methionine aminopeptidases. C* denotes oxidized Cys, either
Cys-sulfinate or Cys-sulfonate, produced in reactions mediated by nitric oxide
(NO), oxygen (O2) and their derivatives. OxidizedN-terminal Cys is arginylated
by ATE1-encoded isoforms of R-transferase (2–4). Type-1 and type-2 primary
destabilizing N-terminal residues are recognized by the pathway’s E3 Ub
ligases, called N-recognins (9). Through their other substrate-binding sites,
these E3s also recognize internal (non-N-terminal) degrons in other substrates
of the N-end rule pathway, denoted by a larger oval. (B and C) Heme regula-
tory motifs (HRMs) in R-transferases. Numbers refer to position of the last
residue of a shown sequence in the corresponding protein. A disulfide be-
tween Cys-71 and Cys-72 refers to hemin-mediated inhibition of ATE1. (D) The
mouse ATE11B7A isoform (2), with locations of significant Cys-containing
motifs.
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Fig. 2. Heme binds to arginyl-transferase and inhibits its activity. (A) Hemin-
mediated inhibition of arginylation by mouse ATE11B7A (black bars) and S.
cerevisiae ATE1 (red bars). (B) Comparison of mouse ATE11B7A inhibition by
Fe2-heme (blue bars) and Fe3-heme (hemin) (yellow bars). Red bar, a partial
rescue of hemin-inhibited ATE1 by 10mM 2-mercaptoethanol. (C) Hemin was
added either to buffer alone (curve 1), or to lysozyme, which does not bind to
hemin (curve 2), or to purifiedATE11B7A (curve 3), followedby gel filtration (to
removeunboundhemin) and spectroscopicmeasurements. (D)Determination
of hemin’s affinity for the purified wild-type ATE11B7A (open circles) and its
ATE1C411A mutant (filled circles) (see SI Fig. 7 A–C for unprocessed data).
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forming Cys residues of ATE1, the hemin-exposed and control
ATE1 proteins were treated, respectively, with 1H-NEM (NEM),
i.e., protium (1H)-containing NEM, and with 2H5(D5)-NEM (D-
NEM), i.e., NEM containing nonexchangeable deuterium (2H).
The two ATE1 samples were mixed at 1:1 molar ratio and purified
by SDS/PAGE, and ATE1’s tryptic peptides were analyzed by
MALDI-TOF MS and ESI-MS/MS (Fig. 3). NEM-conjugated
versus D-NEM-conjugated species of a peptide such as C79(H/D-
NEM)HPLQFQPSK were present at close to 1:1 ratio (Fig. 3B). In
contrast, the peptide YVYKPVMDQTC71(H/D-NEM)C72(H/D-
NEM)PQYTIR, which encompassed the only HRM sequence of
ATE1 with vicinal Cys residues (Fig. 1B–D), containedmuchmore
of the heavier, D-NEM-containing species (Fig. 3A), as would be
expected, given the logic of mapping procedure (Fig. 3C), if
hemin-treated ATE1 contained the C71-C72 SOS bond before the
second disulfide-reducing treatment (Figs. 1B and 3C). To verify
this conclusion in a different way, we used the double-mutant
ATE1C71A,C72A (SI Fig. 8). If the C71–C72 disulfide (Fig. 1B) was, in
fact, the single (or nearly so) hemin-induced SOS bond in wild-type
ATE1, it would follow that FM treatment (Fig. 3C) would not result
in a hemin-specific labeling of ATE1C71A,C72A, which lacked both
C71 and C72. This prediction was confirmed (SI Fig. 6 H and I).
Thus, the binding of hemin toATE1 results in the formationof SOS
bond between the vicinal C71 and C72 residues (Figs. 1B and 3).
ATE1C71A,C72A (SI Fig. 8) virtually lacked arginylation activity,
whereas ATE1C71S, the C713 S71 mutant, retained 7% of activity
(SI Fig. 6 D and F). The C71/C72 requirement for the activity of
R-transferase is in agreement with the finding that the hemin-
induced disulfide between C71 and C72 abrogates ATE1 activity
(Figs. 1B, 2 A and B, and 3), at least in part because a disulfide
between vicinal Cys residues is a strained 8-member ring. TheHRM
sequence HSC411P (Fig. 1 C and D) is likely to encompass a
hemin-binding site of ATE1, and may be spatially proximal, in the
folded enzyme, to its N-terminal domain that contains both the
disulfide-forming region C71C72P (Fig. 1B) and the thioredoxin-like
motif C23GYC26 (SI Fig. 8A). In this arrangement, bound hemin
would be close to the region where hemin induces the SOS bond.
Together, our results indicate a redox mechanism of ATE1 inhi-
bition by hemin (SI Fig. 9D). In this mechanism, the intramolecular
C71–C72 disulfide is produced through a spatially localized oxidation
of C71–C72 by the ATE1-bound hemin (Fe3-heme), in conjunction
with a coupled reduction of hemin to Fe2-heme (SI Fig. 9D). This
model, which remains to be definitively verified, also explains the
observed difference between hemin (Fe3-heme) and Fe2-heme
in regard to inhibition of ATE1 (Fig. 2B).
Hemin Induces Degradation of R-Transferase in Vivo. A mouse cell
line, termed 3T3offATE1tap, expressed ATE11B7A with C-terminal
TAP tag (see SI Text). Cells were adapted to growth in a serum-free
medium and thereafter treated for 10 h with 7 M hemin. Re-
markably, both the endogenous (untagged) ATE1 and ATE1tap
were strongly decreased by hemin (Fig. 4F), through the induced
degradation of ATE1, as could be shown directly by a pulse–chase
assay (Fig. 4 I and J). This effect could also be observed by
measuring the arginylation activity of R-transferase in cell extracts
(Fig. 4 E andG). Hemin was previously shown to induce the in vivo
degradation of Bach1, a heme-binding transcription factor (22), and
of IRP2, a heme-binding translational regulator (17). A test with
MG132, a proteasome inhibitor, indicated that hemin-mediated
ATE1 degradation was proteasome-dependent, and also suggested
that ATE1 was a substrate of the Ub-proteasome system (albeit to
a lower extent) even in the absence of added hemin (Fig. 4H).
We also constructed 21mutants ofATE11B7A (SI Fig. 8C–E) and
characterized their sensitivity to hemin in vitro, focusing onmutants
that retained at least 90% of R-transferase activity (SI Fig. 8 C–E).
ATE1mutants with alterations in the HRM-like motif C79HP were
as sensitive to inhibition by hemin as was wild-type ATE1 (SI Fig.
11A). In contrast, ATE1 mutants that contained the C4113 A411
mutation in the HRM motif HSC411P (Fig. 1C), exhibited both a
significantly lower affinity for hemin and higher resistance to
inhibition by hemin (Fig. 2D and SI Fig. 11A). To explore these
results in vivo, we constructed a cell line, termed
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3T3offATE1C411A,P412Atap, that expressed ATE1C411,P412Atap, a
double mutant at the HRMmotif HSC411P (Fig. 1C). In agreement
with the in vitro findings (Fig. 2D and SI Fig. 11A), the in vivo
down-regulation of wild-type ATE1 by hemin was much stronger
than that of ATE1C411,P412A (SI Fig. 11B). (The actual difference
must be even higher than the observed one, because
3T3offATE1C411A,P412Atap cells expressed not only
ATE1C411A,P412Atap but also, at lower levels, the endogenous,
hemin-sensitive ATE1.) Thus, the down-regulation of ATE1 by
hemin in vivo (Fig. 4 E–J) is mediated primarily (possibly solely) by
the binding of hemin to ATE1.
Other constructed mouse cell lines expressed, through the Ub
fusion technique (1, 2), two RGS4-based reporters: Asp-RGS4h
(ATE1-dependent N-end rule substrate) and Arg-Asp-RGS4h
(ATE1-independent N-end rule substrate) (Fig. 1A), with ‘‘h’’
denoting His6. Another cell line expressed UbG76V-Val-RGS4h, a
reporter with a ‘‘nonremovable’’ Ub moiety that is targeted for
degradation by a non-N-end rule pathway called the UFD pathway
(25). The levels of Cys-RGS4h and Asp-RGS4h, whose in vivo
degradation requires arginylation, were strongly increased by he-
min, with a significant increase already at 1Mhemin (Figs. 1A and
4A and B). This increase was mediated largely, possibly entirely, by
the binding of hemin to ATE1, as indicated by the above result with
ATE1C411,P412A (SI Fig. 11B) and also, independently, by the finding
that the levels of RGS16 (a G protein regulator naturally expressed
in fibroblasts) were strongly increased by hemin in wild-type
fibroblasts but not in ATE1/ fibroblasts (SI Fig. 11C). [RGS4,
RGS5 andRGS16 are physiological N-end rule substrates that bear
N-terminal Cys (3, 4).] Thus, while increasing the rate of in vivo
degradation of ATE1 (Fig. 4 E–J), hemin decreases the rate of
degradation of a physiological ATE1 substrate such as RGS16 (SI
Fig. 11C), at least in part through a decrease in the in vivo level of
ATE1 (R-transferase).
Interestingly, Arg-Asp-RGS4h, the ATE1-independent N-end
rule substrate (Fig. 1A), was detectably stabilized only at 5 Mand
higher levels of hemin, in contrast to Cys-RGS4h and Asp-RGS4h
(Fig. 4 A and B, compare C). This pattern suggests a differential,
fine-tuned response to heme by specific parts of the N-end rule
pathway (Fig. 1A), a finding to be explored. UbG76V-Val-RGS4h, a
reporter substrate of a non-N-end rule pathway (25), was detectably
stabilized only at 10 M hemin (Fig. 4D, compare A and B). Thus,
hemin can inhibit not only the N-end rule pathway, but also (at
higher concentrations) other Ub-dependent pathways as well (Figs.
1A and 4 A–C). More than 25 years ago, the addition of hemin (at
levels an order of magnitude higher than above) to an extract from
reticulocytes was shown to inhibit degradation of some proteins in
the extract (ref. 26 and references therein).
Hemin Blocks the Activation of N-End Rule’s Ubiquitin Ligase.Extracts
from mouse 3T3 cells were subjected to hemin-agarose chroma-
tography and immunoblotting for UBR1 (SI Fig. 7D). Both UBR1
and UBR2 were found to bind to hemin, with UBR2 examined by
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Fig. 4. Hemin induces degradation of arginyl-transferase in vivo. (A) A mouse cell line expressing His6-tagged Cys-RGS4 (Cys-RGS4h) (3), was exposed for 10 h
to hemin (denoted as ‘‘h’’) in themedium, followedby SDS/PAGE and immunoblotting of cell extractswith anti-RGS4 antibody. (B) Samebut a cell line expressing
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with hemin in the medium. (G) Quantitation, by autoradiography of 14C-lactalbumin, of the data in E. (H) Lanes 1 and 2, ATE1 in NIH 3T3 cells, detected by
immunoblotting in the absence of hemin treatment and either the absence or presence of 5 MMG132. Lanes 3 and 4, same but with hemin at 10 M for 10 h
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a similar assay, employing an extract from S. cerevisiae that ex-
pressedmouse UBR2 tagged with the flag epitope (SI Fig. 7C, lane
1). Several otherwise dissimilar mouse E3s, termed UBR4-UBR7,
have in common the UBR domain (which is also present in UBR1
and UBR2) and have been shown to behave, in binding assays, as
N-recognins (9). These E3s also contain HRM motifs. One such
N-recognin, the 300-kDa mouse UBR5 (EDD/hHYD), was exam-
ined and found to interact with hemin (data not shown), similarly
to mouse UBR1 and UBR2. Two substrate-binding sites of yeast
UBR1, the sole N-recognin of S. cerevisiae, bind, respectively, to the
type-1 (basic) and type-2 (bulky hydrophobic) destabilizing N-
terminal residues of either protein-sized substrates or short peptides
(Fig. 1A) (1, 8, 10). The third binding site ofUBR1 targets (through
an internal degron) the transcriptional repressor CUP9, which
controls a regulon that includes PTR2, the importer of short
peptides (8). Peptides bearing type-1 or type-2 N-terminal residues
(Fig. 1A) interact with the corresponding sites of UBR1, and
allosterically activate its (autoinhibited) third site, which targets
CUP9. Through this positive feedback, mediated by the conditional
degradation of CUP9, S. cerevisiae can sense the presence of
extracellular peptides and react by accelerating their uptake (8, 10).
The activation, by dipeptides, of the UBR1-CUP9 interaction can
be reconstituted in vitro (Fig. 5A and SI Fig. 10 G and H) (8).
Whereas fUBR1 did not bind to CUP9 in the presence of Ala–Leu
and Ala–Arg (dipeptides with a stabilizing N-terminal residue), the
binding of CUP9 was activated in the presence of Arg-Ala and
Leu-Ala, bearing type-1/2 N-terminal residues (Figs. 1A and 5A,
lane 2 vs. 3) (8).
Remarkably, the addition of hemin inhibited the binding of
UBR1 to CUP9 irrespective of the presence of binding-activating
dipeptides. The inhibition was essentially complete at 50Mhemin
(Fig. 5 and SI Fig. 10G). Previous work (8) has shown that the
autoinhibition of CUP9-binding site of UBR1 (its default state, in
the absence of type-1/2 dipeptides) requires full-size UBR1, in that
UBR11–1140, its N-terminal half, could bind to CUP9 in either the
presence or absence of dipeptides (8). We found that ,whereas
hemin inhibited the dipeptide-mediated activation ofCUP9binding
by full-length UBR1, hemin had no effect, even at 0.1 mM, on the
binding of CUP9 to C-terminally truncated UBR11–1140 (Fig. 5A
and SI Fig. 10 G and H). [Both full-length UBR1 and UBR11–1140
have affinity for hemin, similarly to mouse UBR2 (SI Fig. 10C).]
Hemin did not affect the ability of full-length UBR1 to recognize
destabilizing N-terminal residues (SI Fig. 10I). Thus, hemin does
not directly occlude the substrate-binding sites of UBR1, but blocks
a conformational transition (8) that underlies the allosteric activa-
tion (mediated by type-1/2 dipeptides) of the CUP9-binding site of
UBR1 (Fig. 5 B and C). Hemin did not appear to have an in vivo
proteolytic effect on mouse UBR1 (data not shown).
Concluding Remarks
We discovered that the ATE1-encoded R-transferase, which me-
diates the arginylation branch of the N-end rule pathway (Fig. 1A),
is a heme-binding enzyme in both fungi and mammals. The
arginylation activity of ATE1s was inhibited by low-micromolar
levels of hemin (Fe3-heme), through a redox mechanism that
produces disulfide between vicinal Cys-71 and Cys-72 of mouse
ATE1. Remarkably, hemin was also found to induce the protea-
some-dependent degradation ofR-transferase in vivo, thus acting as
both a ‘‘stoichiometric’’ and ‘‘catalytic’’ down-regulator of the
N-end rule pathway. The mechanism through which hemin up-
regulates the in vivo degradation of ATE1 remains to be analyzed.
The above ‘‘dual’’ repression of R-transferase by hemin greatly
increased the in vivo levels of N-end rule substrates such as RGS4
and RGS16 (Fig. 4A and SI Fig. 11C), which control the signaling
by G proteins. Hemin also binds to the yeast and mouse Ub ligases
of the N-end rule pathway (Fig. 1A). The binding of hemin to S.
cerevisiaeUBR1 blocks the activation of one of its substrate-binding
sites (Fig. 5 B and C). The N-end rule pathway, a known sensor of
short peptides, NO and oxygen (2–4, 8, 10), and a regulator of
biological processes cited in Introduction, is now a sensor of heme
as well. One function of this proteolytic circuit may be to coordinate
the redox dynamics of heme, NO, oxygen, thiols, and other small
effectors, by sensing them through components of the N-end rule
pathway, and by acting to alter the levels, activity or spatiotemporal
gradients of these compounds, in part through the conditional
degradation of transcriptional regulators such as CUP9 and c-FOS
(8, 10, 12) or regulators of G proteins such as RGS4, RGS5 and
RGS16 (3, 4).
The inhibition of R-transferase by Fe3-heme (hemin) is a
property of this enzyme that is conserved from fungi to mammals.
What physiology of the heme-ATE1 connection underlied selective
pressures that led to the emergence and retention of this property
over vast phylogenetic distances? Given the cardiovascular defects
of ATE1/ embryos (7), their low levels of embryonic globin and
heme, high levels of heme oxygenase (SI Fig. 6 A–C), and their
perturbedhematopoiesis (J. Sheng,R.-G.H., andA.V., unpublished
data), the N-end rule pathway is likely to play a role in the control
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Fig. 5. Hemin inhibits activation of CUP9 binding by the UBR1 ubiquitin
ligase. (A) Equal amounts of extract from S. cerevisiae expressing fUBR1 were
incubated with glutathione-Sepharose beads preloaded with GST-CUP9, in
ether the presence or absence of indicated dipeptides (at 1 mM each) (8), and
either in the absence or presence of hemin, at indicated levels. The bound
proteins were eluted, fractionated by SDS/PAGE and immunoblotted with
anti-flag antibody. Lane 1, input sample (3% of extract’s amount used in
GST-pulldowns). Lane 2, fUBR1 and GST-CUP9 in the presence of Ala-Leu and
Ala-Arg (note the absence of interaction between UBR1 and CUP9). Lane 3,
samebut in thepresenceof Leu-Ala andArg-Ala. Lanes 4–7, sameas lane3but
in the presence of 1, 10, 100, or 200 M hemin. Lanes 8 and 9, same as lanes
2 and 3, respectively, but in the absence of 1 mM NaOH (a control, because 1
mM NaOH was present in other samples (lanes 2–7), owing to the NaOH-
containing hemin’s stock solution). (B and C) A diagram (based in part on the
present findings) of interactions amongst UBR1, dipeptides with type-1 or -2
destabilizing N-terminal residues, and the CUP9 transcriptional repressor. See
the main text.
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of heme synthesis, transport, and/or catabolism. RGS4 is a down-
regulator of tubulogenesis, a process that underlies the develop-
ment and homeostasis of blood vessels and other tubular structures
such as those of the mammary gland, kidney and the lung (27).
Heme-mediated inhibition of theN-end rule pathway (Fig. 1A) and
the resulting increase in the levels of N-end rule substrates such as
RGS4 and RGS16 (Fig. 4 A–C and SI Fig. 11C) would be expected
to inhibit tubulogenesis. BothRGS4 andRGS16 block the signaling
by VEGF, whereas RGS5 (another physiological N-end rule sub-
strate) was implicated in the control of vessel remodeling during
neovascularization (27, 28). Thus, in addition to the discovery of a
link between heme and R-transferases (Fig. 1A), one physiological
insight of the present work is that the N-end rule pathway is a
mediator of heme’s effects on tubulogenesis. The sensor–effector
link between theN-end rule pathway and hememay be relevant not
only to normal conditions but also to perturbations of heme
homeostasis, for example upon a ‘‘spontaneous’’ or wound-induced
hemorrhage, or in a hemorrhage-prone setting of a growing tumor.
Our identification of the G protein regulators RGS4, RGS5, and
RGS16 asNO-dependentN-end rule substrates (3), and the present
discovery that the N-end rule pathway is a sensor of both heme and
NO (Fig. 1A) adds a new dimension to the involvement of NO in
heme-mediated processes (16).
Over the last decade, it became clear that reactive oxygen species
(ROS) such as H2O2, if they are present at ‘‘signaling’’ (i.e.,
sufficiently low) levels, can act as regulators of circuits that underlie
not only stress responses but also other functions, including the cell
cycle, transcription and differentiation (reviewed in ref. 24). ROS-
mediated signaling utilizes cysteine-containing protein sensors,
some of which contain heme as well. A direct connection, through
the N-end rule pathway, between heme and protein degradation
(Fig. 1A) may also play a role in the multifaceted regulation by
‘‘signaling’’ levels of H2O2 and other ROS compounds. This aspect
of our findings remains to be explored.
In contrast toO2 andCO, which bind only to Fe2-heme,NO can
interact with either Fe3-heme (hemin) or Fe2-heme. The latter
is apparently inactive as an efficacious inhibitor of ATE1 (Fig. 2B).
Moreover, the hemin moiety bound to NO usually undergoes rapid
autoreduction to Fe2-heme. Thus, in addition to its role in
converting proteins withN-terminal Cys into ‘‘arginylatable’’ N-end
rule substrates (3) (Fig. 1A), NO may also counteract the hemin-
mediated inhibition of ATE1. In other words, besides making
possible (through oxidation of N-terminal Cys) the arginylation of
Cys-bearing ATE1 substrates (3), NO may also up-regulate the
targeting of all ATE1 substrates, including those with N-terminal
Asp or Glu (Fig. 1A), by protecting ATE1 (R-transferase) from
down-regulation by hemin.
It is likely that the set of arginylation-dependent N-end rule
substrates is much larger than the three RGS proteins above. For
example, yet another such substrate is a separase-produced frag-
ment of mammalian cohesin, whose stabilization in mouse
ATE1/ cells (which lack arginylation) results in chromosome
instability (J.Zhou, J. Sheng,R.G.H., andA.V., unpublisheddata).
The simultaneous sensitivity of the N-end rule pathway to heme,
NO, oxygen, short peptides, and redox may underlie the ability of
cells to integrate the often divergent effects of small compounds to
produce functionally adaptive outputs.
Methods Summary
Fordescriptionsofmaterialsandmethods, seeSIText, SI Figs.6–11,SITables1and
2,andassociatedreferences.MouseATE11B7AR-transferase(2),S.cerevisiaeATE1,
andATE11B7Amutants (SI Fig. 8), were produced and purified as described in ref.
3 and SI Text. Spectroscopic assays were performed as described (16–18). Mea-
surementsofhemeoxygenase,heme,andembryonic -globin chainwere carried
with extracts from wild-type and ATE1/ mouse embryos. Arginylation assays
were carried out with 14C-Arg, the -lactalbumin reporter, and purified S. cer-
evisiae or mouse R-transferase (or, alternatively, with extracts from mouse cells
either treatedoruntreatedwithhemin) (2, 3), as described in SI Text. Tryptophan
fluorescence quenching assay and the mapping of disulfide in ATE1 are also
describedinSIText. FormethodsusedtocharacterizehemeinteractionswithUBR
proteins, seerefs.8and9andSIText. Forconstructionofmousecell linesandtheir
use, see SI Text.
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